Scientists, experts and entrepreneurs from Wroclaw have been recognized in the Most Creative Minds in Business Ranking published by Brief magazine.
His company is focused on developing innovative veterinary products. It is currently working on, among others, biopharmaceuticals that utilize the immunomodulatory properties of mesenchymal stem cells. The company is also the first in Europe to introduce a safe treatment for animals based on allogenic stem cells – thanks to which one donor can help several recipients.
Read more here.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...Article
Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...Article
According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...Article
Gazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...Article
We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...Article
Wrocław scientists in the comfort of laboratories are preparing drugs that change the standards of treating dogs, cats and horses. Just a little ...Read full
As the first company in Europe, Bioceltix intends to authorize a veterinary biopharmaceutical based on stem cells. Łukasz Bzdzion, the CEO of the ...Read full
We was on Impact’18, congress that brings leaders at the forefront of innovation from many sectors together to explore the opportunities ...Read full